Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center and 2025 Influential Woman in Oncology by OncoDaily, shared a post on X:
“Mary Jo Fidle, Rush University presents a complex case of a young patient with locally advanced EGFR NSCLC started on indefinite osimertinib after chemoRT and wants to get pregnant.
Is if safe to stop osimertinib consolidation and for how long?”
Did you know that Estela Rodriguez has been listed as “100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2025” by OncoDaily?
